EU Antibiotic Resistance Deaths 2026: What New ECDC Surveillance Report on Superbugs Means

ECDC Report Reveals 46,000 EU/EEA Deaths from Antibiotic Resistance in 2025

The European Centre for Disease Prevention and Control (ECDC) released its 2026 annual antimicrobial resistance (AMR) surveillance report today, 28 August 2026, confirming that antibiotic-resistant infections caused 46,000 deaths across the EU/EEA in 2025. This figure represents a stark increase from previous years and confirms that EU antibiotic resistance deaths 2026 remain a critical public health emergency, with carbapenem-resistant Enterobacterales rising another 4.7% between 2024 and 2025, making it the fastest-growing high-risk resistance pattern across Europe. The report, based on data from all 27 EU member states plus Norway and Iceland, demands immediate policy action.

Speaking at the Brussels press conference this morning, Dr. Andrea Ammon, ECDC Director, stated: "We are at a tipping point. The 46,000 deaths we record today are not abstract statistics. These are patients who entered European hospitals for routine procedures and acquired infections that no longer respond to our strongest antibiotics. We cannot normalise this loss." The ECDC has now formally called on all member states to adopt mandatory national targets for antibiotic consumption, noting that per-capita use continues to rise in nine member states despite the EU Action Plan goals set for 2024.

Which EU Countries Are Worst Affected by Superbugs in 2026?

The ECDC surveillance data for August 2026 reveals significant geographic disparities across the European Union. The highest burden of antimicrobial-resistant infections continues to concentrate in Southern and Southeastern Europe, with Italy, Greece, and Romania reporting healthcare-associated infection rates substantially above the EU average. The report identifies that 11 EU countries report healthcare-associated infection rates above the EU average, including Bulgaria, Croatia, Hungary, Poland, and Slovakia in addition to the three worst-affected nations.

According to the ECDC report released on 28 August 2026, the mortality burden is not evenly distributed. Italy accounts for approximately 22% of all AMR-attributable deaths in the EU/EEA, followed by Greece at 12% and Romania at 9%. By contrast, Nordic countries including Sweden and Finland report the lowest rates, with infection control programmes and strict antibiotic stewardship delivering measurable results. Germany and France, despite their larger populations, have managed to stabilise their resistance rates through national action plans implemented between 2023 and 2025.

Carbapenem Resistance: The Fastest Growing Threat

Carbapenem-resistant Enterobacterales (CRE), often referred to as the "nightmare bacteria," increased by 4.7% across the EU/EEA between 2024 and 2025. These bacteria are resistant to carbapenems, which are typically the last line of defence against multi-drug resistant infections. The ECDC report highlights that CRE bloodstream infections carry a mortality rate of approximately 40% to 50%, compared to 10% for susceptible infections. In Greece and Romania, CRE now accounts for over 30% of all Klebsiella pneumoniae bloodstream isolates in hospital settings, according to the 2026 surveillance data.

Why Superbugs Are Spreading So Fast in European Hospitals

The 2026 ECDC report points to three interconnected drivers behind the accelerating spread of antimicrobial resistance within EU member states. First, hospital transmission remains the primary mechanism, with inadequate hand hygiene compliance and insufficient isolation facilities reported in multiple member states. Secondly, the overuse and misuse of broad-spectrum antibiotics, particularly in Southern Europe, continues to select for resistant strains. Thirdly, the report identifies cross-border patient movement and medical tourism within the EU as an often overlooked factor in resistance gene propagation.

Professor Evelina Tacconelli, Director of the Infectious Diseases Division at the University of Verona and a leading ECDC consultant, commented in the report: "We have known the solutions for a decade. Hand hygiene campaigns, antibiotic stewardship programmes, and infection control teams work. The problem is implementation. Some hospitals in Italy and Greece have fewer than half the infection control nurses they need, and patients are dying because of this resource gap."

Routine Procedures Becoming High-Risk

The social impact of this data is profound and immediate. EU patients undergoing routine procedures such as hip replacements, caesarean sections, or even urinary catheter insertion are now facing heightened risks of acquiring infections that cannot be treated with standard antibiotics. The ECDC estimates that patients infected with carbapenem-resistant bacteria face hospital stays extended by 10 to 21 days, with associated costs ranging from €15,000 to €40,000 per patient across EU member states. For low-income households, extended hospitalisation often means lost wages, mounting medical bills, and significant family disruption.

The human cost extends beyond mortality. Survivors of severe resistant infections frequently experience long-term disability, including limb amputation, permanent kidney damage, and chronic pain conditions. The ECDC report estimates that for every death attributable to AMR, there are approximately three additional patients who survive but suffer permanent organ damage or reduced quality of life. This equates to roughly 140,000 EU citizens annually experiencing life-altering consequences from antibiotic-resistant infections.

Hospital Hygiene and Antibiotic Consumption: The Root Causes

The ECDC surveillance report released today provides granular data on antibiotic consumption patterns across EU member states. Per-capita antibiotic consumption continued to rise in nine member states during the period 2024-2025, directly contradicting the goals of the EU Action Plan on AMR. The highest consumers remain Greece (34.1 defined daily doses per 1,000 inhabitants per day), Romania (32.8), and Bulgaria (31.5), compared to the EU average of 20.5. The Netherlands and Sweden maintain the lowest consumption rates at approximately 10-11 DDD per 1,000 inhabitants, demonstrating that national policy can drive significant improvements.

The report highlights a particularly concerning trend of increased consumption of last-resort antibiotics, including carbapenems and polymyxins, across 14 EU member states. This "reserve antibiotic" usage is a strong predictor of future resistance development. The ECDC calls for mandatory reporting of antibiotic use by hospital department, rather than at hospital level only, to identify and correct prescribing patterns at the unit level where change is most needed.

EU Initiatives and the 2026 Policy Landscape

The European Commission is currently negotiating new binding legislation under the EU Pharmaceutical Package, which will include specific AMR provisions. The ECDC report accelerates this process by providing the evidence base for mandatory targets. In July 2026, the Commission proposed a revision to the Council Recommendation on stepping up EU actions to combat AMR, which now includes a draft target of 20% reduction in total human antibiotic consumption by 2030, and a 15% reduction in the use of WHO "Watch" and "Reserve" antibiotics. These targets are under negotiation but face resistance from pharmaceutical industry stakeholders concerned about reduced revenues.

Several member states have already taken unilateral action following the earlier ECDC data signals. France implemented mandatory antibiotic stewardship audits in all public hospitals in January 2026, with penalties for non-compliance. Germany expanded its national surveillance system to include real-time resistance data from all 1,800 acute care hospitals, effective March 2026. Spain announced €150 million in new funding for infection prevention programmes, distributed across its autonomous communities in June 2026. These national initiatives, while welcome, create uneven protection across the EU according to the ECDC report, and the agency stresses that coordinated European-level action remains essential.

What EU Patients Can Do to Protect Themselves

For EU citizens scheduled for hospital admissions or procedures in the coming months, practical protective steps can significantly reduce infection risk. The single most effective measure is to ask your healthcare provider about infection rates at your specific hospital. Many EU member states now publish hospital-specific infection data, and patients have the right to request this information. The ECDC website publishes annual country-level data, and several national health portals offer facility-level comparisons. If your hospital reports above-average resistance rates, discuss whether your procedure can be performed at an alternative facility.

Second, patients should request a "molecular diagnostic test" if they develop a fever or signs of infection during or after hospitalisation. These rapid tests, available in most EU tertiary hospitals, identify the specific bacteria and resistance genes within hours rather than the 48-72 hours required for traditional culture methods. Early identification allows for targeted therapy rather than broad-spectrum antibiotics, reducing both treatment failure risk and your personal contribution to resistance selection.

Antibiotic Stewardship at Home

Outside hospital settings, EU citizens can contribute to reducing antibiotic resistance through responsible use. Never pressure your doctor or pharmacist for antibiotics for viral infections such as common colds or influenza. If antibiotics are prescribed, complete the full course exactly as directed, and never share antibiotics with family members or keep leftovers for future illnesses. The ECDC notes that self-medication with leftover antibiotics remains a significant problem in Southern European member states, and urges proper disposal through community pharmacy take-back schemes.

Related Reading

• EU Workers: How New Right to Disconnect Rules Impact Work-Life Balance
• Europe's GP Shortage: What It Means for Patient Access and Healthcare Systems
• UK Alcohol Harm Report: How New Data Impacts Public Health Policy Today
• UK Air Quality Regulations: What New Proposals Mean for Health

Frequently Asked Questions

What is the new ECDC data on antibiotic resistance deaths in the EU for 2026?

The ECDC report published on 28 August 2026 shows that antimicrobial-resistant infections caused 46,000 deaths in the EU/EEA during 2025. This is the highest annual figure ever recorded by the agency, and it excludes deaths where resistant infections contributed to but did not directly cause death, which the ECDC estimates at an additional 110,000 cases.

Which European countries have the highest rates of antibiotic-resistant infections?

Italy, Greece, and Romania report the highest rates of healthcare-associated antibiotic-resistant infections in the 2026 ECDC surveillance data. Eleven EU member states report infection rates above the EU average, including Bulgaria, Croatia, Hungary, Poland, and Slovakia. Nordic countries and the Netherlands report the lowest rates.

How is the European Union responding to the 2026 superbug crisis?

The European Commission is negotiating binding targets under the EU Pharmaceutical Package and a revised Council Recommendation on AMR, including a proposed 20% reduction in antibiotic consumption by 2030. Individual member states have implemented national plans, with France introducing mandatory stewardship audits in 2026 and Germany establishing real-time resistance surveillance.

Are carbapenem-resistant infections treatable with any antibiotics?

Carbapenem-resistant Enterobacterales (CRE) are resistant to most beta-lactam antibiotics, including the carbapenem class. Some CRE strains remain susceptible to newer combinations such as ceftazidime-avibactam or meropenem-vaborbactam, but resistance to even these agents is emerging. The mortality rate for CRE bloodstream infections is approximately 40-50% in EU hospitals.

Summary and Next Steps for EU Healthcare

The ECDC surveillance report published on 28 August 2026 represents a definitive warning to all EU member states. With 46,000 deaths attributable to AMR in 2025 and carbapenem-resistant Enterobacterales increasing by 4.7% year-on-year, the current trajectory is unsustainable. The mandatory national targets on antibiotic consumption and the proposed 20% reduction by 2030 must be adopted and rigorously enforced. EU citizens can play a role through responsible antibiotic use, hospital-specific infection rate inquiries, and support for national stewardship programmes. The latest EU health policy analysis provides further context on how these hospital-level issues intersect with broader continental health trends.

The agency has made an explicit recommendation that each EU member state embed infection prevention and control teams in all hospitals above 150 beds by 2027, and that national surveillance data be updated in real time. For broader insights on how healthcare systems across Europe are addressing systemic public health challenges, readers can explore Baba International's EU policy coverage. The next formal review of the progress on these recommendations will occur at the ECDC annual meeting in Stockholm in November 2026, where member states will be expected to report their baseline consumption and infection targets.